InflaRx NV (IFRX)
2.445
+0.08
(+3.16%)
USD |
NASDAQ |
May 20, 16:00
2.445
0.00 (0.00%)
After-Hours: 20:00
InflaRx Cash from Investing (Quarterly) : 7.182M for March 31, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Liminatus Pharma, Inc. | 0.00 |
| Oruka Therapeutics, Inc. | -14.44M |
| MapLight Therapeutics, Inc. | 67.01M |
| Kailera Therapeutics, Inc. | -- |
| QIAGEN NV | 211.47M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -8.648M |
| Cash from Financing (Quarterly) | -0.0874M |
| Free Cash Flow | -44.56M |
| Free Cash Flow Per Share (Quarterly) | -0.1198 |
| Free Cash Flow to Equity (Quarterly) | -8.467M |
| Free Cash Flow to Firm (Quarterly) | -8.642M |
| Free Cash Flow Yield | -26.89% |